<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="63247"><DrugName>AKT-10081</DrugName><DrugSynonyms><Name><Value>AKT-10081</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>antimicrobial peptide (clostridium difficile), Akthelia</Value></Name><Name><Value>4-phenyl-buturate, Akthelia</Value></Name></DrugSynonyms><CompanyOriginator id="1047040">Akthelia Pharmaceuticals</CompanyOriginator><CompaniesSecondary><Company id="1047040">Akthelia Pharmaceuticals</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1047040" type="Company"><TargetEntity id="5035525704" type="organizationId">Akthelia ehf</TargetEntity></SourceEntity><SourceEntity id="102" type="ciIndication"><TargetEntity id="10012735" type="MEDDRA"></TargetEntity><TargetEntity id="D003967" type="MeSH"></TargetEntity><TargetEntity id="-957779542" type="omicsDisease"></TargetEntity><TargetEntity id="380" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="746" type="ciIndication"><TargetEntity id="10021789" type="MEDDRA"></TargetEntity><TargetEntity id="D007239" type="MeSH"></TargetEntity><TargetEntity id="-367065996" type="omicsDisease"></TargetEntity><TargetEntity id="799" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="995" type="ciIndication"><TargetEntity id="3913" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1594" type="Action"><TargetEntity id="5053" type="Mechanism">Anti-Diphtheria Toxin</TargetEntity><TargetEntity id="5306" type="Mechanism">Drugs Targeting Mycobacterium tuberculosis Proteins</TargetEntity><TargetEntity id="3878" type="Mechanism">Drugs Targeting Bacterial Chaperones</TargetEntity><TargetEntity id="1060" type="Mechanism">Efflux Pump (Bacterial) Inhibitors</TargetEntity><TargetEntity id="4493" type="Mechanism">Drugs Targeting Campylobacter jejuni Proteins</TargetEntity><TargetEntity id="2409" type="Mechanism">Carbon Monoxide-Releasing Agents</TargetEntity><TargetEntity id="4457" type="Mechanism">Drugs Targeting Staphylococcus aureus Proteins</TargetEntity><TargetEntity id="4563" type="Mechanism">Anti-Diphteria Toxin (Corynebacterium diphtheriae)</TargetEntity><TargetEntity id="3994" type="Mechanism">Drugs Targeting Pseudomonas aeruginosa Proteins</TargetEntity><TargetEntity id="3697" type="Mechanism">Drugs Targeting Escherichia coli Proteins</TargetEntity><TargetEntity id="5353" type="Mechanism">Drugs Targeting Clostridium tetani Proteins</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="102">Diarrhea</Indication><Indication id="746">Infectious disease</Indication><Indication id="995">Clostridium difficile infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="4007">Antidiarrhoeal</Action><Action id="1593">Antimicrobial</Action><Action id="1594">Antibacterial</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="80">Peptide</Technology></Technologies><EphmraCodes><Ephmra><Code>A7</Code><Name>ANTIDIARRHOEALS, ORAL ELECTROLYTE REPLACERS AND INTESTINAL ANTI-INFLAMMATORIES</Name></Ephmra><Ephmra><Code>J1</Code><Name>SYSTEMIC ANTIBACTERIALS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-10-23T16:59:29.000Z</LastModificationDate><ChangeDateLast>2018-10-23T00:00:00.000Z</ChangeDateLast><AddedDate>2009-04-27T13:08:58.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1047040" linkType="Company"&gt;Akthelia&lt;/ulink&gt; was developing  AKT-10081 (4-phenyl-buturate; PBA), a small re-purposed/reprofiled antimicrobial peptide for the potential treatment of   gastrointestinal infections, presumed to be bacterial infections,    including Clostridium difficile infection and watery diarrhea   [&lt;ulink linkID="1003378" linkType="Reference"&gt;1003378&lt;/ulink&gt;], [&lt;ulink linkID="1003416" linkType="Reference"&gt;1003416&lt;/ulink&gt;], [&lt;ulink linkID="1256376" linkType="Reference"&gt;1256376&lt;/ulink&gt;], [&lt;ulink linkID="2078728" linkType="Reference"&gt;2078728&lt;/ulink&gt;]. The company is also investigating AKT-10081, for the potential treatment of kidney complication [&lt;ulink linkID="2078728" linkType="Reference"&gt;2078728&lt;/ulink&gt;].  In January 2012, the peptide was listed as being in phase II development [&lt;ulink linkID="1256376" linkType="Reference"&gt;1256376&lt;/ulink&gt;]. In November 2015, this was still the case [&lt;ulink linkID="1713929" linkType="Reference"&gt;1713929&lt;/ulink&gt;].  [&lt;ulink linkID="2078728" linkType="Reference"&gt;2078728&lt;/ulink&gt;]. In January 2012,  the company's strategy involved seeking to outlicense its programs after  phase II  for late stage development and marketing [&lt;ulink linkID="1256376" linkType="Reference"&gt;1256376&lt;/ulink&gt;]. However,  in October 2018,  the development of the program was discontinued  [&lt;ulink linkID="2078728" linkType="Reference"&gt;2078728&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Akthelia was previously investigating AKT-10081 as an adjuvant for the potential treatment of tuberculosis  [&lt;ulink linkID="1003378" linkType="Reference"&gt;1003378&lt;/ulink&gt;], [&lt;ulink linkID="1003416" linkType="Reference"&gt;1003416&lt;/ulink&gt;]. However, no further development has been reported since April 2009. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;By April 2009, phase II studies were expected in the fourth quarter of that year, which were expected to complete by the first quarter of 2010 [&lt;ulink linkID="1003378" linkType="Reference"&gt;1003378&lt;/ulink&gt;], [&lt;ulink linkID="1003416" linkType="Reference"&gt;1003416&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2009, preclinical data were presented at the Sixth AngloNordic Biotech Conference in London, UK. In a rabbit shigellosis model, where infected rabbits died within 40 h, those treated with AKT-10081 all lived beyond 120 h and bacteria were found to have reduced [&lt;ulink linkID="1003378" linkType="Reference"&gt;1003378&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1047040">Akthelia Pharmaceuticals</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="102">Diarrhea</Indication><StatusDate>2018-10-03T00:00:00.000Z</StatusDate><Source id="2078728" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1047040">Akthelia Pharmaceuticals</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="746">Infectious disease</Indication><StatusDate>2018-10-03T00:00:00.000Z</StatusDate><Source id="2078728" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1047040">Akthelia Pharmaceuticals</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate>2009-04-23T00:00:00.000Z</StatusDate><Source id="1003378" type="CONFERENCE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1047040">Akthelia Pharmaceuticals</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate>2012-01-20T00:00:00.000Z</StatusDate><Source id="1256376" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1047040">Akthelia Pharmaceuticals</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="995">Clostridium difficile infection</Indication><StatusDate>2012-01-20T00:00:00.000Z</StatusDate><Source id="1256376" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="1184551" number="WO-2009087474" title="Agonists for antimicrobial peptide systems"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Akthelia Pharmaceuticals" id="1047040"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>